Perspectives of immunotherapy in metastatic breast cancer

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4599-4604

  Lüftner, Diana ^a   Pollmann, D ^a   Schildhauer, S ^a   Sehouli, J ^a   Possinger, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Circulating HER 2 neu; Herceptin; Immunotherapy; Metastatic breast cancer; Review; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL RESPONSE MODIFIER; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD LEVEL; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG APPROVAL; DRUG EFFICACY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; METASTASIS; NEUTROPENIA; ONCOGENE NEU; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASM METASTASIS;

EID: 28444439496     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Rowinsky EK: Signal events: cell signal transduction and its inhibition in cancer. Oncologist 8 Suppl 3: 5-17, 2003.
2. Rowinsky EK: Crossing the cancer cell membrane to improve clinical outcomes. Oncologist 8 Suppl 3: 1-4, 2003.
3. Alaoui-Jamali MA and Qiang H: The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery. Drug Resist Updat 6(2): 95-107, 2003.
4. Holbro T, Civenni G and Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 284(1): 99-110, 2003.
5. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L et al: HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22(21): 3205-3212, 2003.
6. Siwak DR, Mendoza-Gamboa E and Tari AM: HER2/neu uses Akt to suppress retinoic acid response element binding activity in MDA-MB-453 breast cancer cells. Int J Oncol 23(6): 1739-1745, 2003.
7. Woods Ignatoski KM, Grewal NK, Markwart S, Livant DL and Ethier SP: p38MAPK induces cell surface alpha4 integrin down-regulation to facilitate erbB-2-mediated invasion. Neoplasia 5(2): 128-134, 2003.
8. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S and Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62(14): 4132-4141, 2002.
9. Witton CJ, Reeves JR, Going JJ, Cooke TG and Bartlett JM: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200(3): 290-297, 2003.
10. Amin DN, Perkins AS and Stern DF: Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene 23(7): 1428-1438, 2004.
11. Paik S, Bryant J, Tan-Chiu E, Romond E, Miller W, Park K et al: Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94(11): 852-854, 2002.
12. Hanna W: Testing for HER2 status. Oncology 61 Suppl 2: 22-30, 2001.
13. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B et al: Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19(2): 354-363, 2001.
14. Izumi Y, Xu L, di Tomaso E, Fukumura D and Jain RK: Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416(6878): 279-280, 2002.
15. Albanell J, Codony J, Rovira A, Mellado B and Gascon P: Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 532: 253-268, 2003.
16. Baselga J, Albanell J, Molina MA and Arribas J: Mechanism of action of trastuzumab and scientific update. Semin Oncol 28(5 Suppl 16): 4-11, 2001.
17. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11): 783-792, 2001.
18. Extra J, Cognetti F, Chans S, Maraninchi D, Snyder R, Lluch A et al: Randomised phase II trial (M77001) of trastuzumab (Herceptin) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer. Eur J Cancer 1: S202 (#672), 2004.
19. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y et al: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8(5): 459-465, 2002.
20. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P et al: Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96(10): 759-769, 2004.
21. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D et al: Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 76: S37, 2002.
22. Rowland K, Suman V, Ingle J, Loprinzi C, Flynn P, Krook J et al: NCCTG 98-32-52: randomized phase II trial of weekly versus every 3-week administration of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer (MBC). J Clin Oncol 22: 8, 2003.
23. Buzdar A, Hunt K, Smith T, Francis D, Ewer M, Booser D et al: Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. J Clin Oncol 22: #520, 2004.
24. Trigo J, Climent M, Llunch A, Gascon P, Hornedo J, Gil M et al: Liposomal doxorubicin Myocet in combination with Herceptin and paclitaxel is active and well tolerated in patients with HER2-positive locally advanced or metastatic breast cancer: a phase II study. Breast Cancer Res Treat 82: #253, 2003.
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785): 177-182, 1987.
26. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G et al: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85(17): 1419-1424, 1993.
27. Pantel K, Muller V, Auer M, Nusser N, Harbeck N and Braun S: Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res 9(17): 6326-6334, 2003.
28. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F et al: Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18(1): 80-86, 2000.
29. Slamon D and Pegram M: Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28(1 Suppl 3): 13-19, 2001.
30. Tan-Chiu E and Piccart M: Moving forward: Herceptin in the adjuvant setting. Oncology 63 Suppl 1: 57-63, 2002.
31. Geyer C, Bryant J, Romond E, Tan-Chia E, Ewer M, Keete D et al: Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC). Breast Cancer Res Treat 82: #23, 2004.
32. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16(8): 2659-2671, 1998.
33. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20(7): 1800-1808, 2002.
34. Kostler WJ, Schwab B, Singer C, Neumann R, Marton E, Brodowicz T et al: Predictive value of serum HER-2/neu extracellular domain (ECd) during trastuzumab-based therapy in patients with breast cancer. Proc AACR 43: 490, 2002.
35. Lüftner D, Schaller G, Henschke P, Felsenstein S, Geppert R and Possinger K: Evaluation of serum HER-2/neu for outcome assessment and monitoring of Herceptin plus combination chemotherapy in metastatic breast cancer. Breast Cancer Res Treat 76(1): S110 (#427), 2002.
36. Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA et al: Relationship of serum HER-2/neu and serum CA 153 in patients with metastatic breast cancer. Clin Chem 48(8): 1314-1320, 2002.